4,635 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Purchased by Cibc World Markets Corp

Cibc World Markets Corp purchased a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 4,635 shares of the company's stock, valued at approximately $362,000.

A number of other large investors have also added to or reduced their stakes in PBH. JPMorgan Chase & Co. grew its stake in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after purchasing an additional 8,533 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock worth $95,678,000 after buying an additional 50,961 shares during the period. Avior Wealth Management LLC grew its position in shares of Prestige Consumer Healthcare by 1,570.7% in the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after buying an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after buying an additional 33,844 shares during the period. Finally, Barclays PLC raised its holdings in shares of Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after acquiring an additional 71,730 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Remove Ads

Prestige Consumer Healthcare Stock Up 1.3 %

PBH stock traded up $1.07 on Thursday, reaching $86.07. 339,718 shares of the company traded hands, compared to its average volume of 260,161. The firm has a fifty day simple moving average of $83.17 and a 200-day simple moving average of $78.89. The company has a market cap of $4.26 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

PBH has been the subject of several research reports. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Tuesday, March 18th. DA Davidson lifted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and an average target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.